Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

An anti-αVβ3 antibody inhibits coronary artery atherosclerosis in diabetic pigs.

Maile LA, Busby WH, Xi G, Gollahan KP, Flowers W, Gafbacik N, Gafbacik S, Stewart K, Merricks EP, Nichols TC, Bellinger DA, Clemmons DR.

Atherosclerosis. 2017 Mar;258:40-50. doi: 10.1016/j.atherosclerosis.2017.01.030. Epub 2017 Jan 27.

PMID:
28189040
2.

Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet.

Nichols TC, Merricks EP, Bellinger DA, Raymer RA, Yu J, Lam D, Koch GG, Busby WH Jr, Clemmons DR.

PLoS One. 2015 Jul 6;10(7):e0132302. doi: 10.1371/journal.pone.0132302. eCollection 2015.

3.

Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs.

Maile LA, Busby WH, Gollahon KA, Flowers W, Garbacik N, Garbacik S, Stewart K, Nichols T, Bellinger D, Patel A, Dunbar P, Medlin M, Clemmons D.

Endocrinology. 2014 Dec;155(12):4665-75. doi: 10.1210/en.2014-1318. Epub 2014 Aug 29.

4.

Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells.

Cascella T, Radhakrishnan Y, Maile LA, Busby WH Jr, Gollahon K, Colao A, Clemmons DR.

Endocrinology. 2010 Dec;151(12):5851-64. doi: 10.1210/en.2010-0350. Epub 2010 Sep 29.

5.

Adiponectin lowers glucose production by increasing SOGA.

Cowherd RB, Asmar MM, Alderman JM, Alderman EA, Garland AL, Busby WH, Bodnar WM, Rusyn I, Medoff BD, Tisch R, Mayer-Davis E, Swenberg JA, Zeisel SH, Combs TP.

Am J Pathol. 2010 Oct;177(4):1936-45. doi: 10.2353/ajpath.2010.100363. Epub 2010 Sep 2. Erratum in: Am J Pathol. 2011 Mar;178(3):1406. Cowerd, Rachael B [corrected to Cowherd, Rachael B].

6.

A monoclonal antibody against alphaVbeta3 integrin inhibits development of atherosclerotic lesions in diabetic pigs.

Maile LA, Busby WH, Nichols TC, Bellinger DA, Merricks EP, Rowland M, Veluvolu U, Clemmons DR.

Sci Transl Med. 2010 Feb 10;2(18):18ra11. doi: 10.1126/scitranslmed.3000476.

7.

Insulin-like growth factor-I-stimulated insulin receptor substrate-1 negatively regulates Src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells.

Radhakrishnan Y, Busby WH Jr, Shen X, Maile LA, Clemmons DR.

J Biol Chem. 2010 May 21;285(21):15682-95. doi: 10.1074/jbc.M109.092270. Epub 2010 Mar 5.

8.

Identification of compounds that inhibit IGF-I signaling in hyperglycemia.

Maile LA, Allen LB, Veluvolu U, Capps BE, Busby WH, Rowland M, Clemmons DR.

Exp Diabetes Res. 2009;2009:267107. doi: 10.1155/2009/267107. Epub 2010 Jan 6.

9.

Complement 1s is the serine protease that cleaves IGFBP-5 in human osteoarthritic joint fluid.

Busby WH Jr, Yocum SA, Rowland M, Kellner D, Lazerwith S, Sverdrup F, Yates M, Radabaugh M, Clemmons DR.

Osteoarthritis Cartilage. 2009 Apr;17(4):547-55. doi: 10.1016/j.joca.2008.08.004. Epub 2008 Oct 18.

10.

Modulation of integrin antagonist signaling by ligand binding of the heparin-binding domain of vitronectin to the alphaVbeta3 integrin.

Maile LA, Aday AW, Busby WH, Sanghani R, Veluvolu U, Clemmons DR.

J Cell Biochem. 2008 Oct 1;105(2):437-46. doi: 10.1002/jcb.21841.

11.

Protease-resistant insulin-like growth factor (IGF)-binding protein-4 inhibits IGF-I actions and neointimal expansion in a porcine model of neointimal hyperplasia.

Nichols TC, Busby WH Jr, Merricks E, Sipos J, Rowland M, Sitko K, Clemmons DR.

Endocrinology. 2007 Oct;148(10):5002-10. Epub 2007 Jul 19.

PMID:
17640990
12.

Role of the integrin alphaVbeta3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress.

Clemmons DR, Maile LA, Ling Y, Yarber J, Busby WH.

Growth Horm IGF Res. 2007 Aug;17(4):265-70. Epub 2007 Apr 6. Review.

13.

The heparin binding domain of vitronectin is the region that is required to enhance insulin-like growth factor-I signaling.

Maile LA, Busby WH, Sitko K, Capps BE, Sergent T, Badley-Clarke J, Ling Y, Clemmons DR.

Mol Endocrinol. 2006 Apr;20(4):881-92. Epub 2005 Dec 1.

PMID:
16322097
14.

Insulin-like growth factor-I signaling in smooth muscle cells is regulated by ligand binding to the 177CYDMKTTC184 sequence of the beta3-subunit of alphaVbeta3.

Maile LA, Busby WH, Sitko K, Capps BE, Sergent T, Badley-Clarke J, Clemmons DR.

Mol Endocrinol. 2006 Feb;20(2):405-13. Epub 2005 Sep 29.

PMID:
16195248
16.

Insulin-like growth factor binding protein-5 (IGFBP-5) interacts with thrombospondin-1 to induce negative regulatory effects on IGF-I actions.

Moralez AM, Maile LA, Clarke J, Busby WH Jr, Clemmons DR.

J Cell Physiol. 2005 May;203(2):328-34.

PMID:
15700281
17.

Regulation of vascular smooth muscle cell responses to insulin-like growth factor (IGF)-I by local IGF-binding proteins.

Hsieh T, Gordon RE, Clemmons DR, Busby WH Jr, Duan C.

J Biol Chem. 2003 Oct 31;278(44):42886-92. Epub 2003 Aug 12.

18.
19.

Testing a GIS model of habitat suitability for a declining grassland bird.

Lauver CL, Busby WH, Whistler JL.

Environ Manage. 2002 Jul;30(1):88-97.

PMID:
12053243
21.

Biochemical and functional analysis of a conserved IGF-binding protein isolated from rainbow trout (Oncorhynchus mykiss) hepatoma cells.

Bauchat JR, Busby WH Jr, Garmong A, Swanson P, Moore J, Lin M, Duan C.

J Endocrinol. 2001 Sep;170(3):619-28.

PMID:
11524242
23.

The complement component C1s is the protease that accounts for cleavage of insulin-like growth factor-binding protein-5 in fibroblast medium.

Busby WH Jr, Nam TJ, Moralez A, Smith C, Jennings M, Clemmons DR.

J Biol Chem. 2000 Dec 1;275(48):37638-44.

24.

Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions.

Imai Y, Moralez A, Andag U, Clarke JB, Busby WH Jr, Clemmons DR.

J Biol Chem. 2000 Jun 16;275(24):18188-94.

25.
26.

A protease-resistant form of insulin-like growth factor (IGF) binding protein 4 inhibits IGF-1 actions.

Rees C, Clemmons DR, Horvitz GD, Clarke JB, Busby WH.

Endocrinology. 1998 Oct;139(10):4182-8.

PMID:
9751498
28.

Insulin-like growth factor-binding protein-5 is cleaved by physiological concentrations of thrombin.

Zheng B, Clarke JB, Busby WH, Duan C, Clemmons DR.

Endocrinology. 1998 Apr;139(4):1708-14.

PMID:
9528953
29.

Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture.

Imai Y, Busby WH Jr, Smith CE, Clarke JB, Garmong AJ, Horwitz GD, Rees C, Clemmons DR.

J Clin Invest. 1997 Nov 15;100(10):2596-605.

31.

Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5.

Parker A, Clarke JB, Busby WH Jr, Clemmons DR.

J Biol Chem. 1996 Jun 7;271(23):13523-9.

32.

Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells.

Parker A, Gockerman A, Busby WH, Clemmons DR.

Endocrinology. 1995 Jun;136(6):2470-6.

PMID:
7538463
33.

Proteolytic cleavage of insulin-like growth factor binding protein 4 (IGFBP-4). Localization of cleavage site to non-homologous region of native IGFBP-4.

Chernausek SD, Smith CE, Duffin KL, Busby WH, Wright G, Clemmons DR.

J Biol Chem. 1995 May 12;270(19):11377-82.

34.

Role of insulin-like growth factor binding proteins in the control of IGF actions.

Clemmons DR, Busby WH, Arai T, Nam TJ, Clarke JB, Jones JI, Ankrapp DK.

Prog Growth Factor Res. 1995;6(2-4):357-66. Review.

PMID:
8817679
35.

Glycosaminoglycans inhibit degradation of insulin-like growth factor-binding protein-5.

Arai T, Arai A, Busby WH Jr, Clemmons DR.

Endocrinology. 1994 Dec;135(6):2358-63.

PMID:
7527332
36.

Human fibroblasts secrete a serine protease that cleaves insulin-like growth factor-binding protein-5.

Nam TJ, Busby WH Jr, Clemmons DR.

Endocrinology. 1994 Oct;135(4):1385-91.

PMID:
7523096
37.
38.

Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence.

Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR.

Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10553-7.

39.

Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children.

Smith WJ, Nam TJ, Underwood LE, Busby WH, Celnicker A, Clemmons DR.

J Clin Endocrinol Metab. 1993 Nov;77(5):1294-9.

PMID:
7521346
40.

A highly conserved insulin-like growth factor-binding protein (IGFBP-5) is expressed during myoblast differentiation.

James PL, Jones SB, Busby WH Jr, Clemmons DR, Rotwein P.

J Biol Chem. 1993 Oct 25;268(30):22305-12.

41.

Role of insulin-like growth factor binding proteins in modifying IGF actions.

Clemmons DR, Jones JI, Busby WH, Wright G.

Ann N Y Acad Sci. 1993 Aug 27;692:10-21. Review. No abstract available.

PMID:
7692784
42.

Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I.

Jones JI, Gockerman A, Busby WH Jr, Camacho-Hubner C, Clemmons DR.

J Cell Biol. 1993 May;121(3):679-87.

43.

Human IGFBP-1 is phosphorylated on 3 serine residues: effects of site-directed mutagenesis of the major phosphoserine.

Jones JI, Busby WH Jr, Wright G, Clemmons DR.

Growth Regul. 1993 Mar;3(1):37-40.

PMID:
7683525
44.
45.

Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs.

Clemmons DR, Dehoff ML, Busby WH, Bayne ML, Cascieri MA.

Endocrinology. 1992 Aug;131(2):890-5.

PMID:
1379166
46.

Identification of the forms of insulin-like growth factor-binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion.

Camacho-Hubner C, Busby WH Jr, McCusker RH, Wright G, Clemmons DR.

J Biol Chem. 1992 Jun 15;267(17):11949-56.

47.

Cloning and sequence determination of bovine insulin-like growth factor binding protein-2 (IGFBP-2): comparison of its structural and functional properties with IGFBP-1.

Bourner MJ, Busby WH Jr, Siegel NR, Krivi GG, McCusker RH, Clemmons DR.

J Cell Biochem. 1992 Feb;48(2):215-26.

PMID:
1377702
48.
49.

Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects.

Clemmons DR, Snyder DK, Busby WH Jr.

J Clin Endocrinol Metab. 1991 Oct;73(4):727-33.

PMID:
1716260
50.

Insulin-like growth factor (IGF) binding to cell monolayers is directly modulated by the addition of IGF-binding proteins.

McCusker RH, Busby WH, Dehoff MH, Camacho-Hubner C, Clemmons DR.

Endocrinology. 1991 Aug;129(2):939-49.

PMID:
1713163

Supplemental Content

Loading ...
Support Center